Clinical trial · Interventional
Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
A Prospective Open-Label Randomized Study of Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is the leading cause of cancer related mortality. At present, surgical treatment is the main choice for early-stage lung cancer. Even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%. Traditional Chinese medicine combined with thermal and cold ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to evaluate the efficacy of traditional Chinese medicine combined with thermal and cold ablation for patients with stage I non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer Stage I | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ablation | Procedure | — | UNRESOLVED |
| traditional Chinese medicine and ablation in the primary tumor sites | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- traditional Chinese medicine combined with thermal or cold ablation
- interventionNames
- Combination Product: traditional Chinese medicine and ablation in the primary tumor sites
- type
- ACTIVE_COMPARATOR
- label
- thermal or cold ablation
- interventionNames
- Procedure: ablation
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- 2 years after ablation
- description
- Response were evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee. BEST RESPONSE from the start of study treatment until the end of treatment were reported. Objective response rate is the sum of CR + PR divided by the total number of patients in each group.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good. * Patients with lung nodule. * Maximum diameter of lung nodule ≥8mm. * The pathology of lung nodules biopsy was non-small cell lung cancer. * I period according to the eighth edition of the TNM staging period. * No mediastinal lymph node metastasis. * Eastern Cooperative Oncology Group performance status of 0 to 1. * No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. * Sufficient organ functions. Exclusion Criteria: * Patients with previous use of various hormones, immunosuppression or autoimmune diseases. * Women during pregnancy or breast-feeding. * Patients with severe heart, lung, kidney disease or other systemic diseases * Patients with severe hemorrhagic diseases. * Patients with a history of drug abuse or mental illness. * Other conditions that the investigator has determined are not suitable for participation in this study
References
Publications (0)
Data not yet available